YL-15293
Sponsors
Shanghai YingLi Pharmaceutical Co. Ltd.
Conditions
Advanced Solid Tumor
Phase 1
A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation
NCT05119933
Start: 2021-11-09End: 2023-12-01Target: 55Updated: 2021-11-15
Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation
NCT05173805
Start: 2022-01-30End: 2024-12-30Target: 150Updated: 2023-07-18